Category Health & IP

High-Level UN Initiative On Global Public Health Gap Holds Landmark Hearing

An initiative of the United Nations secretary general yesterday gathered what could be described as an assembly of many of the world’s best thinkers and practitioners on public health and intellectual property rights. Industry, activists, academics, international organisations, and possibly some governments poured out their views for nearly seven hours – at times coming to tears and tension – shepherded by an astute moderator, as they responded to the call to take a longstanding debate on medicines access and high prices to a breakthrough.

WHO Welcomes UN Secretary-General’s High-Level Panel, Offers Suggestions

The World Health Organization has provided a list of suggestions to the United Nations Secretary General’s High-Level Panel on Access to Medicines, highlighting WHO activities in this area and making suggestions on areas the WHO has not yet been able to complete. It also describes several new proposals by WHO, including a global “fair pricing forum,” a pooled health product R&D fund, and a global antibiotic research and development facility.

UN Global Dialogue On Innovation And Access To Medicines This Week

The United Nations Secretary General’s High-Level Panel on Access to Medicines is holding a global dialogue this month, attended by governments, civil society, industry and academia, to discuss potential solutions to promote innovation and at the same time increase access to medicines. The first public dialogue session is this week, on 10 March in London.

WHO: Zika Virus Spreading, R&D Needs Financing, Sample Sharing Discussed

The World Health Organization said today that evidence of the relationship between the Zika virus and neonatal malformations and neurological disorders is growing stronger. The Emergency Committee set up by the WHO at a gathering today issued advice to the WHO director general, including warning pregnant women to avoid travelling to Zika infected countries. Meanwhile, discussions are ongoing on the sharing of the samples of the virus, and on the question of benefit-sharing. And a call was made for research and development to intensify.

Alleged R&D Costs: Not A Transparent Driver Of Drug Prices

Whether laws enforcing transparency on costs would help curb extortionate drug prices in today’s world is hardly predictable now that pharma companies and their allies are lobbying governments to scupper any rules that would require them to disclose the real R&D costs and profits of their medicines and the rationale for charging what they do, writes Daniele Dionisio.

Uganda In Clinical Trials For Ebola Vaccine

KAMPALA, Uganda -- An Ebola vaccine trial is underway in Uganda, as the global search for an effective vaccine continues. The vaccine candidate was co-developed by the National Institute of Allergy and Infectious Diseases (NIAID), part of the United States National Institutes of Health (NIH), and GlaxoSmithKline (GSK), a United Kingdom-based pharmaceutical company.